Positron (OTCMKTS:POSC – Get Free Report) is one of 78 publicly-traded companies in the “Electromedical equipment” industry, but how does it contrast to its competitors? We will compare Positron to related companies based on the strength of its dividends, analyst recommendations, valuation, risk, profitability, earnings and institutional ownership.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Positron and its competitors, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Positron | 0 | 0 | 0 | 0 | N/A |
Positron Competitors | 287 | 826 | 2136 | 109 | 2.62 |
As a group, “Electromedical equipment” companies have a potential upside of 2,878.01%. Given Positron’s competitors higher probable upside, analysts plainly believe Positron has less favorable growth aspects than its competitors.
Profitability
Net Margins | Return on Equity | Return on Assets | |
Positron | -300.00% | N/A | -89.57% |
Positron Competitors | -299.08% | -83.96% | -27.59% |
Volatility & Risk
Positron has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Positron’s competitors have a beta of 0.92, meaning that their average share price is 8% less volatile than the S&P 500.
Institutional and Insider Ownership
44.3% of shares of all “Electromedical equipment” companies are held by institutional investors. 17.2% of Positron shares are held by company insiders. Comparatively, 15.1% of shares of all “Electromedical equipment” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Positron and its competitors revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Positron | $740,000.00 | -$1.64 million | -12.13 |
Positron Competitors | $992.46 million | $83.13 million | 9.84 |
Positron’s competitors have higher revenue and earnings than Positron. Positron is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Summary
Positron competitors beat Positron on 8 of the 10 factors compared.
Positron Company Profile
Positron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.
Receive News & Ratings for Positron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Positron and related companies with MarketBeat.com's FREE daily email newsletter.